Har­vard's Gre­go­ry Ver­dine has big am­bi­tions for his minipro­tein 'braces' — and now $107M to guide them to the clin­ic

Har­vard sci­en­tist Gre­go­ry Ver­dine’s mis­sion has al­ways been clear: drug the un­drug­gable. He’s now one step clos­er, with $107 mil­lion in the bank to bring a new class of drugs to the clin­ic — and he isn’t rul­ing out an IPO.

Since launch­ing Fog­Phar­ma in 2016, Ver­dine and his crew have been hard at work on a new kind of ther­a­peu­tic class that com­bines the cell-pen­e­trat­ing ca­pac­i­ty of small mol­e­cules with the tar­get-en­gag­ing tenac­i­ty of bi­o­log­ics. The re­sult is what he calls CPMPs, or cell-pen­e­trat­ing minipro­teins.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN